---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000022"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:22:00.717746+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune CFO Richard Eisenstadt dies unexpectedly; Andrew Shutterly named acting CFO

## Summary
- Richard Eisenstadt, CFO, passed away unexpectedly on June 24, 2024.
- Andrew Shutterly appointed acting CFO effective June 25, 2024; previously Corporate Controller since Feb 2023.
- Company has initiated a search for a permanent replacement CFO.
- Shutterly joined Altimmune in Oct 2020 as Assistant Controller; prior roles at Meso Scale Diagnostics and Deloitte.

## SEC filing metadata
- accession: 0001326190-24-000022
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000022/0001326190-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000022/alt-20240625x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000022
- JSON: https://secwatch.observer/filing/0001326190-24-000022.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000022.txt

## Key facts
- Executive change
  Richard Eisenstadt departed as Chief Financial Officer at Altimmune, Inc..
  - Role: Chief Financial Officer
  source text: following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000022/0001326190-24-000022-index.htm
- Executive change
  Andrew Shutterly was appointed as acting Chief Financial Officer at Altimmune, Inc..
  - Action: appointed
  - Role: acting Chief Financial Officer
  source text: appointed Andrew Shutterly as acting Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000022/0001326190-24-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.